Therefore, a reversible chemoresistance phenotype can be stated to be regulated by the mTOR pathway, and the inhibition of mTOR signaling can be responsible for the tumor phenotype of the minimal residual disease following chemotherapy. This evidence concerns the gene MTOR and neoplasm.